Pharmacogenetics of antidepressant drugs: current clinical practice and future directions.

Abstract

While antidepressants are widely used to treat mood and anxiety disorders, only half of the patients will respond to antidepressant treatment and only one-third of patients experience a full remission of symptoms. The identification of genetic biomarkers that predict antidepressant-treatment response can improve current clinical practice. This is an emerging field known as pharmacogenetics, which comprises of genetic studies on both the pharmacokinetics and pharmacodynamics of treatment response. Recent studies on antidepressant-treatment response have focused on both aspects of pharmacogenetics research, identifying new candidate genes that may predict better treatment response for patients. This paper reviews recent findings on the pharmacogenetics of antidepressant drugs and future clinical applications. Ultimately, these studies should lead to the use of genetic testing to guide the use of antidepressants in clinical practice.

• Authors: Sneha Narasimhan, Falk W Lohoff
• Journal: Pharmacogenomics (Pharmacogenomics) Vol. 13 Issue 4 Pg. 441-64 (Mar 2012) ISSN: 1744-8042 [Electronic] England
• PMID: 22380000 (Publication Type: Journal Article, Review)

Chemical References

• Antidepressive Agents
• Biomarkers, Pharmacological

Topics

• Antidepressive Agents (adverse effects, therapeutic use)
• Anxiety Disorders (drug therapy, genetics)
• Biomarkers, Pharmacological
• Depressive Disorder (drug therapy, genetics)
• Genome-Wide Association Study
• Genotype
• Humans
• Polymorphism, Genetic